AMLX News and Press, Amylyx Pharmaceuticals Inc. From 04/07/24

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 7, 2024) - Faruqi & Faruqi, LLP, a leading national se...

2024-04-07 04:59:02 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead

2024-04-05 15:00:12 ET More on the markets SPY: The Correction May Be Massive S&P 500: International Risk Assessment My Current View Of The Market: April 2024 Edition (Technical Analysis) S&P 500 holds its bullish trend as it defends the 20-day MA yet...

2024-04-04 07:32:38 ET More on Amylyx Pharmaceuticals An ALS Drug Fails Again Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2023 Earnings Call Transcript Mizuho downgrades Amylyx to Neutral a...

- Based on topline results from the Phase 3 PHOENIX trial of AMX0035 in ALS, Amylyx has started a process with the FDA and Health Canada of voluntarily discontinuing the marketing authorizations for RELYVRIO/ALBRIOZA - RELYVRIO/ALBRIOZA will no longer be available for new patients a...

Do you, or did you, own securities of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)? Did you purchase your securities between November 11, 2022 and November 8, 2023, inclusive? Did you lose money in your investment in Amylyx Pharmaceuticals, Inc.? Do you want to discuss your rights? NEW...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 1, 2024) - Faruqi & Faruqi, LLP, a leading national se...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 20, 2024) - Faruqi & Faruqi, LLP, a leading national s...

2024-03-19 09:09:46 ET More on Seelos Therapeutics Seelos Therapeutics files for 3.4M shares secondary offering Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation Seeking Alpha’s Quant Rating on Seelos Therapeutics Histo...

2024-03-18 10:00:18 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...